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Persistent pulmonary hypertension of the
newborn (PPHN) is a devastating illness
characterized by pulmonary hypertension,
right to left shunting ofblood via the fora-
men ovale and the ductus arteriosus and a
structurally normal heart. In the National
Institute of Child Health and Human
Development (NICHD) Neonatal Observa-
tional Study ofPPHN, the incidence (mea-
sured among infants delivered in high risk
centers only) was 1.9/1,000 live births. A
diverse number of processes including
hypoxemia may lead to the dinical picture
recognized as PPHN (1). Fetal hypoxemia
has been shown to occur with maternal
tobacco smoke exposure (2,3). We hypothe-
size that maternal tobacco smoke exposure is
a riskfactorfor PPHN inhernewborn.
Cotinine, a metabolite ofnicotine, is a
useful biological marker for nicotine exposure
and is inwidespread usetovalidateself-report-
ed smoking status (4). Cotinine has a halflife
of 15-40 hr in adults and 37-160 hr in
infants (5). Cotinine levelshave been used as a
measure ofpassive smoking (6,7). Cotinine
levels in maternal serum during the second
trimester ofpregnancy are more predictive of
birthweight thansmokinghistory(g).
We undertook a study to investigate the
association between maternal and fetal
nicotine exposure and PPHN, using coti-
nine as a biomarker ofexposure.
Methods
Subject. The study took place at Childrens
Hospital Oakland, a referral hospital, from
January 1991 through June 1992. PPHN
was suspected on the basis ofclinical obser-
vation ofthe lability ofoxygenation and/or
disparity between pre- and postductal oxy-
gen saturation as assessed by pulse oxime-
try and confirmed by two-dimensional
echocardiography demonstrating a right to
left shunt. Patients with PPHN were
excluded ifany ofthe following were pre-
sent: confirmed sepsis, chromosomal
abnormality, diaphragmatic hernia, or
structural congenital heart defect. A total
of 36 infants met criteria for enrollment;
three families dedined to participate. After
informed consent was obtained, 33 fami-
lies completed a detailed questionnaire; of
these, 31 newborns had cord blood (19
samples) or newborn blood (12 samples)
cotinine concentrations determined.
All study infants required mechanical
ventilation. Sixteen (51.6%) also received
high frequency ventilation, and 16 (51.6%)
were placed on extracorporeal membrane
oxygenation. Only 5 infants (16.1%)
received mechanical ventilation alone. The
study infants' mean maximum alveolar-arte-
rial oxygengradient (AaDO2) on afractional
inspired oxygen (FiO2) of 1.0 [AaDO2 =
713 - (PAco2 + PA02) where Paco2 is the
arterial CO2 pressure and Pa02 is the post-
ductal arteral 02 pressure] was 644.3 ± 16.9
with a range of614-670 and a median of
644. For 27 ofthese infants, the mean oxy-
genation index (OI) [IU = (100)(Paw)
(FiO2/Pao2) where Paw is the mean airway
pressure] at the peak oftheir disease was 51
± 39.4with arange of11-200 andamedian
of41.
A reference comparison group of 49
healthyinfantswas constructed to beroughly
equivalent to the distribution ofmaternal eth-
nicity in the PPHN group. Infants were fre-
quency matched by maternal ethnicity from
the normal newborn nurseries at two repre-
sentative referral hospitals to form the group.
The referencecomparisongroupwas frequen-
cy matched on maternal ethnicity because
both the incidence ofsmokingand the rate of
nicotine metabolism have been shown to vary
with ethnicity (9-11). Matching in a
case-control study can introduce selection
bias, which itselfacts as a confounder (12);
the result is that the crude estimate ofeffect
underestimates the correct value. This error
can be corrected by treating the matching
variable, maternal ethnicity, as a confounder
and controlling for it in the analysis. Seven
families refused to participate. After informed
consent was obtained, 42 families completed
thequestionnaire and39 hadcordbloodcoti-
nine levels determined. The questionnaire
was administered by an interviewer regarding
exposure to tobacco and other agents during
the pregnancy. The T-ACE questions were
induded in thequestionnaire to assess alcohol
use (13). The T-ACE questionnaire is a sim-
ple and quick method ofidentifing prenatal
risk dfinking. It consists offive questions: T)
How many drinks does it take to make you
feelhigh? (Score 2 if>2drinks);A) Havepeo-
ple annoyed you bycriticizingyour drinking?
(Score 1 ifyes); C) Have you felt you ought
to cut down on your drinking? (Score 1 if
yes); and E) Have you ever had a drink first
thing in the morning to steadyyour nerves or
get rid ofa hangover? (Score 1 ifyes). For a
total score of >2, the specificity is 89% and
sensitivity is 69% at identifying women who
are consuming >1 oz absolute alcohol per day
(13).
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Cotinine analysis. Cord blood for the
comparison group and either cord blood or
earliest available newborn blood from the
study infants was obtained from the blood
bank at the time of enrollment into the
study. Both sources ofbloodwill be referred
to as infant's blood in this paper. Serum or
plasma was separated, extracted with meth-
ylene chloride, and analyzed for cotinine by
gas chromatography-mass spectroscopy
(GC-MS) using a Hewlett-Packard 5970
mass selective detector (Mountain View,
CA) with a 15 m DB-1 fused silica column
(0.25-mm id, 0.25 m film thickness, J & W
Scientific, Folsom, CA). The amount of
cotinine present in asamplewas obtained by
determining the ratio of the peak area for
the protium form molecular ion to the
trideuterium form. The minimum
detectable concentration ofthe plasma coti-
nine was 1 ng/ml. The GC-MS analyses
were done by a blinded investigator.
Duplicate samples gave identical results.
Statistical analysis. Graphical and uni-
variate statistics were used initially to
describe the data and determine the appro-
priateness of parametric or nonparametric
tests ofsignificance. Nominal variables were
described as frequencies, ordinal or non-
parametric interval variables are described
by medians and ranges, and interval, para-
metric data are described by means and
standard deviations (SD). The sample char-
acteristics of the mothers and the infants
were examined to determine ifany unantic-
ipated differences between the groups exist-
ed. Nominal variables were tested using chi-
squared analysis or Fisher's exact test as
appropriate; two sample t-tests were used
for normally distributed data, and Mann-
Whitney (or two sample Wilcoxon rank
sum) tests were used for skewed data. Any
variable with ap-value <0.2 was considered
for entry into a multivariate model to con-
trol for residual confounding.
The association between cotinine levels
and disease status was examined in two
phases. Cotinine levels <1 are classified by
definition as undetected; values >1 were
therefore classified as detected, and the over-
all association was tested first on a nominal
scale using chi-square analysis; the result was
reported as an unadjusted odds ratio. The
continuous portion ofthe measures ofcoti-
nine (those values >1) were compared using
theappropriate nonparametric test.
Since matching on a variable known to
be associated with the exposure in a
case-control study can introduce selection
bias (12), logistic regression was used to
adjust the odds ratio accordingly, with eth-
nicity added as an indicator variable. None
ofthe maternal characteristics were consid-
ered significantly different according to the
above definition and were not included in
the model.
Most statistical analyses were carried out
on a Gateway 2000 486 microcomputer (N.
Sioux City, SD) using STATIT software
(Statware, Inc., Corvallis, OR), all running
under SCO UNIX. PC software such as
SAS (SAS System, SAS Institute, Cary, NC)
and SPlus (Stat-Sci, Seattle, WA) were also
used forsomespecificanalyses.
Results
Maternal characteristics are shown in Table
1. As planned, there was no significant dif-
ference in the ethnic distribution of the
two groups. No significant differences in
maternal education, age, gravidity, or pari-
ty between the study and comparison fami-
lies were noted.
Infant characteristics are shown in
Table 2. There was no significant differ-
ence in birth weight, although the gesta-
tional age as determined by estimated date
of confinement (EDC) was significantly
longer for the PPHN group (40.6 vs. 39.5
weeks;p = 0.0037). This difference is clini-
cally insignificant. When birth weight is
corrected for gestational age, there is no
significant difference. Apgar scores at 1 and
5 min were significantly lower in the
PPHN group as expected.
Maternal report oftobacco use is shown
in Table 3. Women were classified as 1)
active smokers ifthey had smoked at any
time during pregnancy, 2) passive smokers
if they had daily passive smoke exposure
until the time of delivery, or 3) never
smoked or had quit smoking prior to preg-
nancy and had minimal passive smoke
exposure. Due to the small number ofnon-
smoking women who reported dailypassive
smoke exposure, the analysis was conducted
comparing exposed women (active and pas-
sive smoke exposure) versus nonexposed
women. There was a borderline statistically
significant difference in self-reported smok-
ing between the two groups (p = 0.080).
However, due to the small sample size, this
study lacks sufficient power to detect a dif-
ference ofthis magnitude (power = 0.50).
Table 1. Maternal characteristics
PPHN Comparison group
Characteristics (n=31) (n=39) p-value Test
Maternal Ethnicity
White 14 15 0.805 x2
Black 9 14
Other(Hispanic andA4ian) 8 10
Gravidity
1 9 9
2 6 11 0.662 X2
3 or greater 16 19
Parity
1 12 15
2 9 14 0.774 x2
3 or greater 10 10
Maternal education, years 11.8 + 4.0 12.7 ± 4.2 0.422 Mann-Whitney
(mean ± SD)
Maternal age, years 30.1 ± 6.3 28.6 ± 6.1 0.316 Student's t-test,
(mean ±SD) 2-tailed
Abbreviations: PPHN, persistentpulmonary hypertension ofthe newborn; SD, standard deviation.
Table2 Infant characteristics
PPHN Comparison group
Characteristics (n=31) (n=39) p-value Test
Birthweight, g 3621 689 3411 529 0.152 Student's t-test,
(mean ± SD) 2-tailed
Gestational age,weeks 40.6 ± 1.6 39.5± 1.7 0.0037 Student's t-test,
(mean± SD) 2-tailed
Apgarscore, 1 min
0-3 11 0 <0.0001 Mann-Whitney
4-6 12 2
7-10 8 37
Apgar score, 5 min
0-3 4 0 <0.0001 Mann-Whitney
4-6 10 0
7-10 17 39
Abbreviations: PPHN, persistent pulmonary hypertension ofthe newborn; SD, standard deviation.
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Maternal exposures other than tobacco,
which were obtained by questionnaire, are
shown in Table 4. Due to the small num-
ber of study participants with exposure,
dose and timing ofexposure were not ana-
lyzed. Table 4 represents the number of
women who were exposed at least once
during the pregnancy to the chemicals list-
ed and their T-ACE scores. No significant
differences were observed, with the excep-
tion ofantinausea preparations.
The cotinine concentrations of the
newborn's blood were compared to mater-
nal self-reported smoking status (Fig. 1).
Two women who reported no smoking had
cord blood cotinine concentrations consis-
tent with active smoking. To determine if
our results agreed with external studies, we
used the previously published interval val-
ues defining cotinine concentration by
smoking status: no exposure <1 ng/ml; pas-
sive smoke exposure, 1-13.7 ng/ml; and
active smoker >13.7 ng/ml (14). We
looked at our data by reported smoking
status to determine if the cotinine values
Table3. Maternal smoking status
PPHN, Comparison group,
n=31(%) n=39(%)
Exposure status
(Byquestionnaire)
Nonexposed 19(61.3) 31(79.5)
Exposed 12(38.7) 8(20.5)b
Dailypassive 4(12.9) 2(5.1)
Active8 8(25.8) 6(15.4)
Abbreviations: PPHN, persistent pulmonary hyper-
tension ofthe newborn.
"Smoked any amountduring pregnancy.
bp = 0.080 by Fisher's ExactTest(1-tailed).
Table 4. Maternal exposures
Comparison
PPHN group p-value,
Characteristics (n=31) (n=39) FET
Caffeine" 15 22 0.6307
Vitamins 28 37 0.6489
Antacidsb 15 11 0.1345
Antinausea prescriptonsc 7 0 0.0022
Aspirin and NSAIDd 4 4 1.0
Tylenol 20 23 0.8052
Antibiotics 5 4 0.4959
Ethanol" 14 19 0.813
T-ACE>2 9 5 0.1333
Opiatesf 3 1 0.3152
Cocaine 2 2 1.000
Abbreviations: PPHN, persistent pulmonary
hypertension of the newborn; FET, Fisher's Exact
Test; NSAID, nonsteroided anti-inflammatory
drugs.
aCoffee, cola,fiorinal.
b'Tums, Rolaids, Maalox, Mylanta.
CCompazine, Phenergan.
dAspirin, ibuprofen, fiorinal, Alka Seltzer, Pepto-
Bismol.
eDrank any amount during pregnancy.
fHeroin, methadone, codeine.
agreed or disagreed with the literature
based intervals. Results are shown in Table
5. There was a significant association
between our data and literature-based data
(chi-squarep = 0.025).
Cotinine concentrations were compared
between the infants with PPHN and the
comparison group (Fig. 2). Cotinine was
detectable in the blood of 64.5% (20/31)
study infants and 28.2% (11/39) compari-
son infants (p = 0.002). The distribution of
detectable cotinine concentrations, shown
in Figure 2, is clearly higher in the PPHN
group than in the comparison group (medi-
ans are 5.2 ng/ml for PPHN and 2.0 ng/ml
for comparison; Mann-Whitney one-sided
p-value = 0.051).
To assess the impact of passive smoke
exposure, we reanalyzed the data for both
groups excluding active smokers as defined
by selfreport and/or a cotinine concentra-
tion >13.7 mg/ml (14). The results are
shown in Figure 3. Cotinine was detected
in the blood of 50% (11/22) study infants
as compared to 18% (6/32) comparison
infants (p = 0.015) ofapparently nonsmok-
ing women. The distribution of detectable
cotinine concentrations, shown in Figure
3, is also significantly higher in the PPHN
group (medians are 3.5 ng/ml for PPHN
and 1.65 ng/ml for comparison; Mann-
1,000
- 100
0) 10 aci
NO
Self-reported smoking status
Figure 1. Relationship between maternal self-
reported smoking status and cotinine concentra-
tion of infant's blood. The black horizontal lines
indicate cotinine concentrations of 1 ng/ml and
13.7 ng/ml, which correspond to no exposure (<1
ng/ml), passive (1-13.7 ng/ml), and active (>13.7
ng/ml) smoking.
Abbreviations: PPHN, persistent pulmonary
hypertension ofthe newborn; ND, not detectable.
Table 5. Comparison of study data with published
values
Cotinine
Self-reported concentration Agreement
category No. agrees (%)
No smoking 50 34 68
Passive 6 3 50
Active 14 8 65
Overall 70 45 65
Whitney one-sided p-value = 0.022).
However, these results are based on a small
sample size (n = 17).
To correct for any residual confounding
due to baseline differences in the groups and
any selection bias introduced by the match-
ing method, we performed a logistic regres-
sion analysis. The unadjusted odds ratio
(OR) was 4.68 (95% CI, 1.679-12.755;p =
0.0086), which is consistent with the con-
tingency analysis table (Fig. 2). Ethnicity
was added to the model as indicator vari-
ables, and the adjusted OR was 6.10, cor-
recting for the expected bias toward the null.
While the use of antinausea medications is
asociated with the disease, it is not associat-
ed with the exposure (Fisher's Exact Test, p
= 0.692). In addition, logistic regression
analysis ofonly those patients who did not
use this medication resulted in the same
odds ratio. Because there was no evidence
that the use ofantinausea medications con-
founded the relationship between smoking
and PPHN, no further adjustment was nec-
essary. None of the other possible con-
founding variables met the criterion for
entrance into the model (allp-values >0.2).
Discussion
Our results show that cotinine was more
likely to be found in the blood of infants
with PPHN than in that of comparison
infants, and that the cotinine concentra-
tions were significantly higher in the
PPHN group than in the comparison
group. In addition, to examine the role of
passive smoking, active smokers were
excluded from analysis. The prevalence of
significant concentrations of cotinine was
again higher in the PPHN group, suggest-
ing an association between environmental
tobacco smoke exposure and PPHN.
100
E
.E
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ND
Comparison rrPrP
Figure 2. The distribution of the cotinine concen-
trations of both the comparison (n = 39) and
PPHN (n=31) infants.
Abbreviations: PPHN, persistent pulmonary
hypertension ofthe newborn; ND, not detectable.
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There are several possible explanations
for our findings. First, cotinine may accu-
mulate in the fetal compartment ofcompro-
mised fetuses, giving rise to higher cotinine
concentrations in the newborns' blood. This
is unlikely due to its low ionization con-
stant, pKa1 of 4.8. At physiologic or low
ionization constant, physiologic pH, it will
be predominantly nonionized and thus be
able to rapidly diffuse across the placental
barrier as shown byLucket al. (15).
Second, there may be decreased metabo-
lism of cotinine by the PPHN fetuses, but
that should not result in higher cotinine con-
centrations. Because nicotine and cotinine
both rapidly equilibrate between the mater-
nal-fetal compartments (15) and the mixed
function oxidases have little activity in fetal
liver (16), the majority ofcotinine and nico-
tine must be metabolized by the maternal
liver. Thus, the cotinine half-life in utero is
notdependent onfetal liver metabolism.
Third, the time between the last expo-
sure to tobacco smoke and the blood draw-
ing was shorter for the PPHN group than
for the comparison group. This explana-
tion for our findings is unlikely for several
reasons. Since we used the first blood
obtained after transport ofthe baby to our
hospital in 12 cases, the length of time
between last exposure and blood drawing is
already biased towards a longer interval for
the PPHN infants. Also, the half-life of
cotinine in children is 37-160 hr. The
interval between last exposure and obtain-
ing cord blood would have to differ
between the groups by at least 24 hr to
become significant. One explanation for
such a delay in the comparison group is
100 -
10
Q
1
ND
Comparison PPHN
Figure 3. The distribution of cotinine concentra-
tions of both comparison (n = 32) and PPHN (n = 22)
infants after exclusion of mothers who are active
smokers either by self report or by an infant blood
cotinine concentration greaterthan 13.7 ng/ml.
Abbreviations: PPHN, persistent pulmonary hyper-
tension ofthe newborn; ND, not detectable.
that the mothers smoked less, which is con-
sistent with our findings. The other expla-
nation, that these mothers were hospital-
ized in labor for greater than 24 hr, is not
consistent with our data. In our compari-
son group, no mother had prolonged or
difficult labor. In addition, the majority of
mothers in our study (50/70) did not
report smoking or passive smoke exposure.
Therefore, no interval could be obtained
from them between their last exposure and
time ofbirth.
Finally, PPHN infants could be exposed
to more nicotine while in utero. The only
biological source of nicotine is from expo-
sure to tobacco and other nicotine-contain-
ing plants. While ingestion ofnicotine-con-
taining vegetables may theoretically raise
plasma cotinine levels (17), the amount of
raw vegetables that would need to be con-
sumed to result in detectable levels ofcoti-
nine would require an unusual diet. In
addition, there is no reason to assume that
the diets of the two groups in this study
were different. Thus, the most likely expla-
nation ofour finding is that mothers ofthe
infants with PPHN are exposed to more
tobacco or tobacco products.
We measured cotinine concentrations
in the infants' blood because self-report of
smoking or tobacco smoke exposure is
known to be unreliable. This is evident in
Figure 1 in which cotinine levels exceeded
100 ng/ml in women who denied smoking.
In the PPHN group, cord blood was
unavailable for some infants. In these cases,
cotinine was measured in the first available
blood. None ofthese infants had exposure
to nicotine or cotinine through breast milk
or passive smoking prior to blood sam-
pling. Therefore, collecting blood from
these infants rather than obtaining cord
blood should only decrease the concentra-
tion ofcotinine in their blood.
The prevalence of self-reported active
smoking by mothers of the PPHN and
comparison groups was 27.3 and 14.3%,
respectively. A survey of29,494 women in
California in 1992 found marked ethnic dif-
ferences between tobacco use by self report
(10). Using these ethnic-specific prevalence
rates and the known ethnic composition of
our groups, the expected prevalence of
smoking in the PPHN and comparison
groups is 13.3 and 13.6%, respectively.
Although the prevalence of self-reported
smoking in the PPHN group is almost twice
the expected rate, the prevalence was not
significantly different from expected by chi-
square analysis in either group, although the
power ofchi-square analysis is low.
The prevalence ofsmoking varies both
with maternal ethnicity and socioeconomic
status. A comparison group was construct-
ed to be similar in ethnic representation,
with women from the same geographic
area. Educational level has been widely
used as an indicator ofsocioeconomic level
(18,19). The educational level of PPHN
and comparison group mothers was
obtained by questionnaire and found to be
the same in both groups. Thus, the study
and comparison groups would be expected
to have a similar prevalence ofsmoking.
The characteristics of the infants in the
PPHN and comparison groups differed in
Apgar scores. LowerApgar scores are known
to be associated with PPHN and thuswould
be expected to be lower in the PPHN group
relative to the comparison group (20,21).
In the only other published study inves-
tigating the etiology ofPPHN, self-reported
use ofaspirin, nonsteroidal anti-inflammato-
ry drugs (NSAID), illicit drugs, and tobacco
products were associated with PPHN (22);
only aspirin and NSAID use remained sta-
tistically significant in multivariate analysis.
However, this study did not attempt to
ascertain passive smoke exposure, nor were
biochemical markers of exposure used. In
contrast, we obtained a detailed exposure
history from each study participant. We
found no statistical difference in exposure to
aspirin and NSAID or to cocaine. However,
the numbers ofwomen exposed were small
in both groups, with low power to distin-
guish small differences in exposure between
the two groups. We did find antinausea pre-
scription drug use solely in the PPHN
group. The use of antinausea prescription
drugs should be considered in future studies
of the etiology of PPHN to more fully
delineate theirpossible role.
We are confident that the infants
included in the PPHN group represent a
relativelyhomogenous group. With the dif-
ficulty in establishing the diagnosis of
PPHN (23), we used strict criteria for
inclusion into this study. Only patients
with both a diagnosis of PPHN by the
attending neonatologist and a right to left
shunt demonstrable on echocardiogram
were included for study. These patients
represent critically ill newborns with large
AaDO2 and OI, with nearly half receiving
extracorporeal membrane oxygenation.
Therefore, both active and passive maternal
exposure to tobacco smoke is a risk factor
for PPHN. We encourage pregnant women
to cease smoking and to avoid exposure to
second-hand tobacco smoke.
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The Early Bird Catches the Worm!
In this case "the worm" comes in the form of an unmatched
Dq9 AC EXHenvironmental health educational experience - the 1997 Annual
Educational Conference and Exhibition!
NEHA has already begun working on nextyear's AEC & Exhibition in Washington D.C. (June 28-July 2, 1997)!
Although this year's show will truly be hard to top - that is indeed our mission. We're taking your suggestions from
the 1996 attendee surveys and fine tuning our market research to bring you an even
better educational experience and show nextyear
The presentations and interactions at the1997 AEC & Exhibition will again offeryou the education and teach you the
most current and effective practices thatyou need. The conference will cover topics ranging from food protection,
indoor air quality, onsite wastewater, management and hazardous waste. We are already on our way to lining up top
caliber speakers and exhibitors - all we need is you!
That is why we are offering you this Early Bird Special! Ifyou sign up by December 31, 1996 you can receive the
special full conference rate of $319.00 for members and $419.00 for non-members. This is a $30.00 savings from the
pre-registration feel
NEHA is committed to offering you an unmatched educational experience in 19971 Nowhere else will you find edu-
cational sessions that cover all areas of environmental health!
The D.C. Conference will provide you with an excellent opportunity and forum to advance yourself and your organi-
zation. The environmental health and protection professionals that attend our conferences are very diverse, making the
AEC an extremely valuable networking opportunity as well. In addition, NEHA's AEC & Exhibition is a great way to earn
continuing education contact hours.
"Capitolize on Your Educational Opportunities" and attend the 1997 AEC & Exhibition in D.C.! Remember, the Early
Bird deadline is December 31, 1996! For details, fax (303)691-9490 or mail NEHA, 720 S. Colorado Blvd., Suite 970,
South Tower, Denver, CO 80222.
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